349 related articles for article (PubMed ID: 33410346)
1. The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease.
Talotta R
Immunotherapy; 2021 Feb; 13(3):241-256. PubMed ID: 33410346
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Potential of Janus Kinase Inhibitors for the Management of Interstitial Lung Disease.
Huo R; Guo Q; Hu J; Li N; Gao R; Mi L; Zhang Z; Liu H; Guo Z; Zhao H; Zhang L; Xu K
Drug Des Devel Ther; 2022; 16():991-998. PubMed ID: 35400994
[TBL] [Abstract][Full Text] [Related]
3. Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms.
Montero P; Milara J; Roger I; Cortijo J
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207510
[TBL] [Abstract][Full Text] [Related]
4. Retrospective comparative study of the efficacy of JAK inhibitor (tofacitinib) in the treatment of systemic sclerosis-associated interstitial lung disease.
Junfei Z; Meihua G; Shuai Z; Xiangting L; Zhidan L; Tianming C; Yajing L; Chu T; Lipu S
Clin Rheumatol; 2023 Oct; 42(10):2823-2832. PubMed ID: 37335409
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review.
McGaugh S; Kallis P; De Benedetto A; Thomas RM
Dermatol Ther; 2022 Jun; 35(6):e15437. PubMed ID: 35278019
[TBL] [Abstract][Full Text] [Related]
6. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.
Wang L; Hu Y; Song B; Xiong Y; Wang J; Chen D
Inflamm Res; 2021 Jul; 70(7):753-764. PubMed ID: 34212215
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatment with resveratrol alleviates adjuvant arthritis-interstitial lung disease in rats via modulation of JAK/STAT/RANKL signaling pathway.
Yang G; Lyu L; Wang X; Bao L; Lyu B; Lin Z
Pulm Pharmacol Ther; 2019 Jun; 56():69-74. PubMed ID: 30930172
[TBL] [Abstract][Full Text] [Related]
8. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases.
Kahn J; Deverapalli SC; Rosmarin D
Semin Cutan Med Surg; 2018 Sep; 37(3):198-208. PubMed ID: 30215638
[TBL] [Abstract][Full Text] [Related]
9. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
Lescoat A; Lelong M; Jeljeli M; Piquet-Pellorce C; Morzadec C; Ballerie A; Jouneau S; Jego P; Vernhet L; Batteux F; Fardel O; Lecureur V
Biochem Pharmacol; 2020 Aug; 178():114103. PubMed ID: 32562787
[TBL] [Abstract][Full Text] [Related]
10. JAK-STAT Pathway: A Novel Target to Tackle Viral Infections.
Ezeonwumelu IJ; Garcia-Vidal E; Ballana E
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960648
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma.
Aung WW; Wang C; Xibei J; Horii M; Mizumaki K; Kano M; Okamura A; Kobayashi T; Matsushita T
J Dermatol Sci; 2021 Mar; 101(3):174-184. PubMed ID: 33451905
[TBL] [Abstract][Full Text] [Related]
12. Small molecule drug discovery targeting the JAK-STAT pathway.
Lv Y; Mi P; Babon JJ; Fan G; Qi J; Cao L; Lang J; Zhang J; Wang F; Kobe B
Pharmacol Res; 2024 Jun; 204():107217. PubMed ID: 38777110
[TBL] [Abstract][Full Text] [Related]
13. Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats.
Calbet M; Ramis I; Calama E; Carreño C; Paris S; Maldonado M; Orellana A; Calaf E; Pauta M; De Alba J; Bach J; Miralpeix M
J Pharmacol Exp Ther; 2019 Aug; 370(2):137-147. PubMed ID: 31085698
[TBL] [Abstract][Full Text] [Related]
14. In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors.
Kitanaga Y; Imamura E; Nakahara Y; Fukahori H; Fujii Y; Kubo S; Nakayamada S; Tanaka Y
Rheumatology (Oxford); 2020 Aug; 59(8):1957-1968. PubMed ID: 31764973
[TBL] [Abstract][Full Text] [Related]
15. Janus kinase inhibitors in dermatology: Part I. A comprehensive review.
Chapman S; Kwa M; Gold LS; Lim HW
J Am Acad Dermatol; 2022 Feb; 86(2):406-413. PubMed ID: 34246698
[TBL] [Abstract][Full Text] [Related]
16. JAK inhibitors and systemic sclerosis: A systematic review of the literature.
Moriana C; Moulinet T; Jaussaud R; Decker P
Autoimmun Rev; 2022 Oct; 21(10):103168. PubMed ID: 35944611
[TBL] [Abstract][Full Text] [Related]
17. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
Huang IH; Chung WH; Wu PC; Chen CB
Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
[TBL] [Abstract][Full Text] [Related]
18. Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease.
Xiao H; Zhang GF; Liao XP; Li XJ; Zhang J; Lin H; Chen Z; Zhang X
Int J Rheum Dis; 2018 Feb; 21(2):477-486. PubMed ID: 29316328
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between the JAK2 and TGF-β1 signaling pathways in scleroderma-related interstitial lung disease targeted by baricitinib.
Wang D; Wei Y; Xu L; Zhang J
Adv Rheumatol; 2023 May; 63(1):22. PubMed ID: 37194022
[TBL] [Abstract][Full Text] [Related]
20. Netrin-1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin-Induced Pulmonary Fibrosis.
Sun H; Zhu Y; Pan H; Chen X; Balestrini JL; Lam TT; Kanyo JE; Eichmann A; Gulati M; Fares WH; Bai H; Feghali-Bostwick CA; Gan Y; Peng X; Moore MW; White ES; Sava P; Gonzalez AL; Cheng Y; Niklason LE; Herzog EL
Arthritis Rheumatol; 2016 May; 68(5):1251-61. PubMed ID: 26749424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
